This Phase I trial will assess the safety and pharmacokinetic profile of CVT-3619 in healthy volunteers.
The Phase I program will provide early data on the compound’s potential effects on circulating levels of free fatty acids, which are associated with high blood lipid levels, insulin resistance and other cardiometabolic risk factors.
Louis Lange, chairman and CEO of CV Therapeutics, said: “CVT-3619 is a first in class, potent, orally available new chemical entity that targets yet untreatable aspects of dysfunctional metabolism in these patients. CVT-3619 was invented by CV Therapeutics and represents our fourth clinical program to complement our two approved products.”